fda warning letters compounded semaglutide november 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA cracks down on 'misleading'

Tt cho sc khe tm sinh l Biotin gip duy tr cn bng glucose mu, h tr nhng ngi c nguy c hoc ang sng vi bnh tiu ng

Fourteen products, including Tepezza, indicated for thyroid eye disease, and the leukemia drug Blincyto, achieved blockbuster status in 2025

Wu , Michael Snyder Stanford Cardiovascular Institute #Longevity #Metformin #Omega3 #Exercise #Apelin #MetabolicHealth C-Level Biopharma Executive & Entrepreneur | Advisor in Formulation Development/CMC & Drug Delivery | Translational Drug Development Key Findings of A Major Diabetes Clinical Trial: - No Direct Reversal: After 26 weeks, metformin failed to improve insulin resistance in the liver, muscle, or adipose (fat) tissues of adults with Type 1 diabetes

None of these issues are deal-breakers on their own, but together they paint a picture of a company that could be more straightforward